Concepedia

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard, Fujie Zhang, José A. Hidalgo, Elmira Mamedova, Marcelo Losso, Ploenchan Chetchotisakd, Carlos Brites, Jörg Sievers,

The Lancet Infectious Diseases · 2019 · 198 citations · 19 references

DOI

Concepts

References

19

1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults

K. G. Castro, Jill Ward, Laurence Slutsker et al. · Clinical Infectious Diseases · 1993 · 4.4K citations

, , +16

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

New England Journal of Medicine · 2007 · 1.5K citations · Full text

, , +15

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Sharon Walmsley, Antonio Antela, Nathan Clumeck et al. · New England Journal of Medicine · 2013 · 878 citations · Full text

, , +17

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 546 citations · Full text

, , +12

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 514 citations · Full text

, , +16